NCT07115043 - A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

October 2, 2029

Study Completion Date

October 2, 2029

Conditions

MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)Renal Cell CarcinomaMerkel Cell CarcinomaTriple Negative Breast CancerHead and Neck Squamous Cell CarcinomaGastric Cancer/Gastroesophageal Junction CancerHigh Grade Serous Ovarian Carcinoma

Interventions

DRUG

AZD6750

AZD6750- CD8 guided IL-2

DRUG

rilvegostomig

Rilvegostomig- PD1-TIGIT bispecific antibody

Trial Locations (8)

3002

RECRUITING

Research Site, East Melbourne

15232

NOT_YET_RECRUITING

Research Site, Pittsburgh

49546

RECRUITING

Research Site, Grand Rapids

63110

NOT_YET_RECRUITING

Research Site, St Louis

77030

NOT_YET_RECRUITING

Research Site, Houston

78229

RECRUITING

Research Site, San Antonio

104-0045

NOT_YET_RECRUITING

Research Site, Chūōku

227-8577

NOT_YET_RECRUITING

Research Site, Kashiwa